The EPR effect for macromolecular drug delivery to solid tumors: Improvement of tumor uptake, lowering of systemic toxicity, and distinct tumor imaging in vivo

Advanced Drug Delivery Reviews

Volumn 65, Issue 1, 2013, Pages 71-79

  Maeda, Hiroshi ^a   Nakamura, Hideaki ^a   Fang, Jun ^a  

^a SOJO UNIVERSITY   (Japan)

Author keywords

Cancer; Enhancement of the EPR effect; EPR effect mediators; Fluorescent nanoprobes; Inflammation; Tumor blood vessel architecture; Tumor selective drug delivery; Vascular effectors

Indexed keywords

ANGIOTENSIN I CONVERTING ENZYME INHIBITOR; CANCER; CONTRAST AGENT; DRUG RETENTION; EPR EFFECT; HISTORICAL REVIEW; IMAGING AGENT; IN-VIVO; INFLAMMATION; LOW MOLECULAR WEIGHT; MACROMOLECULAR DRUGS; NORMAL TISSUE; PASSIVE TARGETING; PHYSIOLOGICAL DIFFERENCES; SOLID TUMORS; THERAPEUTIC EFFECTS; TUMOR IMAGING; TUMOR TARGETING; TUMOR UPTAKE; VASCULAR EFFECTORS;

BLOOD VESSELS; DISEASES; DRUG DELIVERY; FLUORESCENCE; MACROMOLECULES; NANOPARTICLES; NANOPROBES; NITRATES; TOXICITY;

TUMORS;

ZINOSTATIN;

BIOCOMPATIBILITY; BLOOD VESSEL PERMEABILITY; DRUG DELIVERY SYSTEM; DRUG RETENTION; DRUG UPTAKE; ENHANCED PERMEABILITY AND RETENTION EFFECT; FLUORESCENCE IMAGING; GALLBLADDER CANCER; HUMAN; HYDROPHOBICITY; INFLAMMATION; KIDNEY CANCER; LIVER METASTASIS; MOLECULAR IMAGING; MOLECULAR WEIGHT; NANOPROBE; NONHUMAN; PANCREAS CANCER; PHARMACOLOGICAL PARAMETERS; PRIORITY JOURNAL; REVIEW; SOLID TUMOR; SURFACE CHARGE; TUMOR VASCULARIZATION;

ANIMALS; ANTINEOPLASTIC AGENTS; CAPILLARY PERMEABILITY; DRUG DELIVERY SYSTEMS; HUMANS; MACROMOLECULAR SUBSTANCES; NANOPARTICLES; NEOPLASMS;

EID: 84873268296     PISSN: 0169409X     EISSN: 18728294     Source Type: Journal    
DOI: 10.1016/j.addr.2012.10.002     Document Type: Review

References (82)

1. Matsumoto K., Yamamoto T., Kamata R., Maeda H. Pathogenesis of serratial infection: activation of the Hageman factor-prekallikrein cascade by serratial protease. J. Biochem. 1984, 96:739-749.
2. Kamata R., Yamamoto T., Matsumoto K., Maeda H. A serratial protease causes vascular permeability reaction by activation of the Hageman factor-dependent pathway in guinea pigs. Infect. Immun. 1985, 48:747-753.
3. Molla A., Yamamoto T., Akaike T., Miyoshi S., Maeda H. Activation of Hageman factor and prekallikrein and generation of kinin by various microbial proteinases. J. Biol. Chem. 1989, 264:10589-10594.
4. Maruo K., Akaike T., Inada Y., Ohkubo I., Ono T., Maeda H. Effect of microbial and mite proteases on low and high molecular weight kininogens. J. Biol. Chem. 1993, 268:17711-17715.
5. Maeda H., Yamamoto T. Pathogenic mechanisms induced by microbial proteases in microbial infections. Biol. Chem. 1996, 377:217-226.
6. 3]bradykinin in ascitic fluid from a patient with gastric cancer. J. Biol. Chem. 1988, 263:16051-16054.
7. Matsumura Y., Kimura M., Yamamoto T., Maeda H. Involvement of the kinin-generating cascade and enhanced vascular permeability in tumor tissue. Jpn. J. Cancer Res. 1988, 79:1327-1334.
8. Matsumura Y., Maruo K., Kimura M., Yamamoto T., Konno T., Maeda H. Kinin-generating cascade in advanced cancer patients and in vitro study. Jpn. J. Cancer Res. 1991, 82:732-741.
9. Maeda H., Noguchi Y., Sato K., Akaike T. Enhanced vascular permeability in solid tumor is mediated by nitric oxide and inhibited by both new nitric oxide scavenger and nitric oxide synthase inhibitor. Jpn. J. Cancer Res. 1994, 85:331-334.
10. Doi K., Akaike T., Horie H., Noguchi Y., Fujii S., Beppu T., Ogawa M., Maeda H. Excessive production of nitric oxide in rat solid tumor and its implication in rapid tumor growth. Cancer 1996, 77:1598-1604.
11. Maeda H., Akaike T., Wu J., Noguchi Y., Sakata Y. Bradykinin and nitric oxide in infectious disease and cancer. Immunopharmacology 1996, 33:222-230.
12. Wu J., Akaike T., Hayashida K., Okamoto T., Okuyama A., Maeda H. Enhanced vascular permeability in solid tumor involving peroxynitrite and matrix metalloproteinase. Jpn. J. Cancer Res. 2001, 92:439-451.
13. Wu J., Akaike T., Maeda H. Modulation of enhanced vascular permeability in tumors by a bradykinin antagonist, a cyclooxygenase inhibitor, and a nitric oxide scavenger. Cancer Res. 1998, 58:159-165.
14. 2 analogue beraprost sodium. J. Drug Target. 2003, 11:45-52.
15. Maeda H., Fang J., Inuzuka T., Kitamoto Y. Vascular permeability enhancement in solid tumor: various factors, mechanisms involved and its implications. Int. Immunopharmacol. 2003, 3:319-328.
16. Matsumura Y., Maeda H. A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent SMANCS. Cancer Res. 1986, 46:6387-6392.
17. Maeda H. The enhanced permeability and retention (EPR) effect in tumor vasculature: the key role of tumor-selective macromolecular drug targeting. Advances in Enzyme Regulation 2001, 189-207. Elsevier Science Ltd., Oxford. G. Weber (Ed.).
18. Maeda H. Tumor-selective delivery of macromolecular drugs via the EPR effect: background and future prospects. Bioconjug. Chem. 2010, 21:797-802.
19. Fang J., Nakamura H., Maeda H. The EPR effect: unique features of tumor blood vessels for drug delivery, factors involved, and limitations and augmentation of the effect. Adv. Drug Deliv. Rev. 2011, 63:136-151.
20. Noguchi Y., Wu J., Duncan R., Strohalm J., Ulbrich K., Akaike T., Maeda H. Early phase tumor accumulation of macromolecules: a great difference in clearance rate between tumor and normal tissues. Jpn. J. Cancer Res. 1998, 89:307-314.
21. Seymour L.W., Miyamoto Y., Maeda H., Brereton M., Strohalm J., Ulbrich K., Duncan R. Influence of molecular weight on passive tumour accumulation of a soluble macromolecular drug carrier. Eur. J. Cancer 1995, 31:766-770.
22. Maeda H., Wu J., Sawa T., Matsumura Y., Hori K. Tumor vascular permeability and the EPR effect in macromolecular therapeutics. J. Control. Release 2000, 65:271-284.
23. Maeda H., Sawa T., Konno T. Mechanism of tumor-targeted delivery of macromolecular drugs, including the EPR effect in solid tumor and clinical overview of the prototype polymeric drug SMANCS. J. Control. Release 2001, 74:47-61.
24. Allen T.M., Cullis P.R. Drug delivery systems: entering the mainstream. Science 2004, 303:1818-1822.
25. Nam T., Park S., Lee S.Y., Park K., Choi K., Song I.C., Han M.H., Leary J.J., Yuk S.A., Kwon I.C., Kim K., Jeong S.Y. Tumor targeting chitosan nanoparticles for dual-modality optical/MR cancer imaging. Bioconjug. Chem. 2010, 21:578-582.
26. Silindir M., Erdoǧan S., Özer A.Y., Maia S. Liposomes and their applications in molecular imaging. J. Drug Target. 2012, 20:401-415.
27. Mahmud A., Xiong X.B., Aliabadi H.M., Lavasanifar A. Polymeric micelles for drug targeting. J. Drug Target. 2007, 15:553-584.
28. Jakobsohn K., Motiei M., Sinvani M., Popovtzer R. Towards real-time detection of tumor margins using photothermal imaging of immune-targeted gold nanoparticles. Int. J. Nanomedicine 2012, 7:4707-4713.
29. Pellegrin P., Fernandez A., Lamb N.J.C., Bennes R. Macromolecular uptake is a spontaneous event during mitosis in cultured fibroblasts: implications for vector-dependent plasmid transfection. Mol. Biol. Cell 2002, 13:570-578.
30. Li S.D., Huang L. Pharmacokinetics and biodistribution of nanoparticles. Mol. Pharm. 2008, 5:496-504.
31. Duncan R., Gaspar R. Nanomedicine(s) under the microscope. Mol. Pharm. 2011, 8:2101-2141.
32. Moghimi S.M., Hunter A.C., Murray J.C. Nanomedicine: current status and future prospects. FASEB J. 2005, 19:311-330.
33. Ogawa M., Regino C.A., Seidel J., Green M.V., Xi W., Williams M., Kosaka N., Choyke P.L., Kobayashi H. Dual-modality molecular imaging using antibodies labeled with activatable fluorescence and a radionuclide for specific and quantitative targeted cancer detection. Bioconjug. Chem. 2009, 20:2177-2184.
34. Keereweer S., Mol I.M., Kerrebijn J.D., Van Driel P.B., Xie B., Jong R.J.B., Vahrmeijer A.L., Löwik C.W. Targeting integrins and enhanced permeability and retention (EPR) effect for optical imaging of oral cancer. J. Surg. Oncol. 2012, 105:714-718.
35. Yu F., Zhang L., Huang Y., Sun K., David A.E., Yanga V.C. The magnetophoretic mobility and superparamagnetism of core-shell iron oxide nanoparticles with dual targeting and imaging functionality. Biomaterials 2010, 31:5842-5848.
36. Gormley A.J., Larson N., Sadekar S., Robinson R., Ray A., Ghandehari H. Guided delivery of polymer therapeutics using plasmonic photothermal therapy. Nano Today 2012, 7:158-167.
37. Drug Delivery in Oncology. From Basic Research to Cancer Therapy 2011, vol. 1-3:1-1689. Wiley-VCH Verlag GmbH & Co. KG, Weinheim, Germany. F. Kratz, P. Senter, H. Steinhagen (Eds.).
38. Senger D.R., Galli S.J., Dvorak A.M., Perruzzi C.A., Harvey V.S., Dvorak H.F. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science 1983, 219:983-985.
39. Dvorak H.F., Nagy J.A., Dvorak J.T., Dvorak A.M. Identification and characterization of the blood vessels of solid tumors that are leaky to circulating macromolecules. Am. J. Pathol. 1988, 133:95-109.
40. Folkman J. Tumor angiogenesis: therapeutic implications. N. Engl. J. Med. 1971, 285:1182-1186.
41. Folkman J. What is the evidence that tumors are angiogenesis dependent?. J. Natl. Cancer Inst. 1990, 82:4-6.
42. Maeda H. Vascular permeability in cancer and infection as related to macromolecular drug delivery, with emphasis on the EPR effect for tumor-selective drug targeting. Proc. Jpn Acad. B Phys. Biol. Sci. 2012, 88:53-71.
43. Akaike T., Noguchi Y., Ijiri S., Setoguchi K., Suga M., Zheng Y.M., Dietzschold B., Maeda H. Pathogenesis of influenza virus-induced pneumonia: involvement of both nitric oxide and oxygen radicals. Proc. Natl. Acad. Sci. U. S. A. 1996, 93:2448-2453.
44. Oda T., Akaike T., Hamamoto T., Suzuki F., Hirano T., Maeda H. Oxygen radicals in influenza-induced pathogenesis and treatment with pyran polymer-conjugated SOD. Science 1989, 244:974-976.
45. Maeda H., Akaike T. Oxygen free radicals as pathogenic molecules in viral diseases. Proc. Soc. Exp. Biol. Med. 1991, 198:721-727.
46. Seki T., Fang J., Maeda H. Enhanced delivery of macromolecular antitumor drugs to tumors by nitroglycerin application. Cancer Sci. 2009, 100:2426-2430.
47. Maeda H. Nitroglycerin enhances vascular blood flow and drug delivery in hypoxic tumor tissues: analogy between angina pectoris and solid tumors and enhancement of the EPR effect. J. Control. Release 2010, 142:296-298.
48. Matsuzawa A., Ichijo H. Redox control of cell fate by MAP kinase: physiological roles of ASK1-MAP kinase pathway in stress signaling. Biochim. Biophys. Acta 2008, 1780:1325-1336.
49. Shiratori K., Jin X., Ilieva I., Koyama Y., Yazawa K., Yoshida K., Kase S., Ohno S. Suppressive effects of astaxanthin against rat endotoxin-induced uveitis by inhibiting the NF-κB signaling pathway. Exp. Eye Res. 2006, 82:275-281.
50. Wlaschek M., Heinen G., Poswig A., Schwarz A., Krieg T., Scharffetter-Kochanek K. UVA-induced autocrine stimulation of fibroblast-derived collagenase/MMP-1 by interrelated loops of interleukin-1 and interleukin-6. Photochem. Photobiol. 1994, 59:550-556.
51. 2 receptor induces multiple cellular responses leading to the proliferation of human renal carcinoma cell lines. Cancer Treat. Res. 2012, 4:195-205.
52. Cao X., Tsukamoto T., Seki T., Tanaka H., Morimura S., Cao L., Mizoshita T., Ban H., Toyoda T., Maeda H., Tatematsu M. 4-Vinyl-2,6-dimethoxyphenol (canolol) suppresses oxidative stress and gastric carcinogenesis in Helicobacter pylori-infected carcinogen-treated Mongolian gerbils. Int. J. Cancer 2008, 122:1445-1454.
53. Maeda H., Matsumura Y., Oda T., Sasamoto K. Cancer selective macromolecular therapeutics: tailoring of an antitumor protein drug. Protein Tailoring for Food and Medical Uses 1986, 353-382. Marcel Dekker, New York. R.E. Feeney, J.R. Whitaker (Eds.).
54. Maeda H., Matsumoto T., Konno T., Iwai K., Ueda M. Tailor-making of protein drugs by polymer conjugation for tumor targeting: a brief review on smancs. J. Protein Chem. 1984, 3:181-193.
55. Maeda H. Polymer conjugated macromolecular drugs for tumor-specific targeting. Polymeric Site-Specific Pharmacotherapy 1994, 95-116. John Wiley & Sons, New York. A.J. Domb (Ed.).
56. He C., Hu Y., Yin L., Tang C., Yin C. Effects of particle size and surface charge on cellular uptake and biodistribution of polymeric nanoparticles. Biomaterials 2010, 31:3657-3666.
57. Lee J.S., Ankone M., Pieters E., Schiffelers R.M., Hennink W.E., Feijen J. Circulation kinetics and biodistribution of dual-labeled polymersomes with modulated surface charge in tumor-bearing mice: comparison with stealth liposomes. J. Control. Release 2011, 155:282-288.
58. Oda T., Morinaga T., Maeda H. Stimulation of macrophage by polyanions and its conjugated proteins and effect on cell membrane. Proc. Soc. Exp. Biol. Med. 1986, 181:9-17.
59. Oda T., Maeda H. Binding to and internalization by cultured cells of neocarzinostatin and enhancement of its actions by conjugation with lipophilic styrene-maleic acid copolymer. Cancer Res. 1987, 47:3206-3211.
60. Oda T., Sato F., Maeda H. Facilitated internalization of neocarzinostatin and its lipophilic polymer conjugate, SMANCS, into cytosol in acidic pH. J. Nat. Cancer Inst. 1987, 9:1205-1211.
61. Nakamura H., Fang J., Gahininath B., Tsukigawa K., Maeda H. Intracellular uptake and behavior of two types zinc protoporphyrin (ZnPP) micelles, SMA-ZnPP and PEG-ZnPP as anticancer agents; Unique intracellular disintegration of SMA micelles. J. Control. Release 2011, 155:367-375.
62. Oda T., Kojima Y., Akaike T., Ijiri S., Molla A., Maeda H. Inactivation of chemotactic activity of C5a by the serratial 56-kilodalton protease. Infect. Immun. 1990, 58:1269-1272.
63. Maeda H., Ueda M., Morinaga T., Matsumoto T. Conjugation of poly (styrene-co-maleic acid) derivatives to the antitumor protein neocarzinostatin: pronounced improvements in pharmacological properties. J. Med. Chem. 1985, 28:455-461.
64. Skinner S., Tutton P., O'Brien P. Microvascular architecture of experimental colon tumors in the rat. Cancer Res. 1990, 50:2411-2417.
65. Konerding M.A., Miodonski A.J., Lametschwandtner A. Microvascular corrosion casting in the study of tumor vascularity: a review. Scanning Microsc. 1995, 9:1233-1244.
66. Hashizume H., Baluk P., Morikawa S., McLean J.W., Thurston G., Roberge S., Jain R.K., McDonald D.M. Openings between defective endothelial cells explain tumor vessel leakiness. Am. J. Pathol. 2000, 1561:1363-1380.
67. Suzuki M., Hori K., Abe I., Saito S., Sato H. A new approach to cancer chemotherapy: selective enhancement of tumor blood flow with angiotensin II. J. Natl. Cancer Inst. 1981, 67:663-669.
68. Hori K., Saito S., Takahashi H., Sato H., Maeda H., Sato Tumor-selective Y. blood flow decrease induced by an angiotensin converting enzyme inhibitor, temocapril hydrochloride. Jpn. J. Cancer Res. 2000, 91:261-269.
69. Iwai K., Maeda H., Konno T. Use of oily contrast medium for selective drug targeting to tumor: enhanced therapeutic effect and X-ray image. Cancer Res. 1984, 44:2115-2121.
70. Konno T., Maeda H., Iwai K., Maki S., Tashiro S., Uchida M., Miyauchi Y. Selective targeting of anticancer drug and simultaneous image enhancement in solid tumors by arterially administered lipid contrast medium. Cancer 1984, 54:2367-2374.
71. Maki S., Konno T., Maeda H. Image enhancement in computerized tomography for sensitive diagnosis of liver cancer and semiquantitation of tumor selective drug targeting with oily contrast medium. Cancer 1985, 56:751-757.
72. Konno T., Maeda H., Iwai K., Tashiro S., Maki S., Morinaga T., Mochinaga M., Hiraoka M.T., Yokoyama I. Effect of arterial administration of high-molecular-weight anticancer agent SMANCS with lipid lymphographic agent on hepatoma: a preliminary report. Eur. J. Cancer Clin. Oncol. 1983, 19:1053-1065.
73. Nagamitsu A., Greish K., Maeda H. Elevating blood pressure as a strategy to increase tumor targeted delivery of macromolecular drug SMANCS: cases of advanced solid tumors. Jpn. J. Clin. Oncol. 2009, 39:756-766.
74. Yasuda H., Yamaya M., Nakayama K., Sasaki T., Ebihara S., Kanda A., Asada M., Inoue D., Suzuki T., Okazaki T., Takahashi H., Yoshida M., Kaneta T., Ishizawa K., Yamanda S., Tomita N., Yamasaki M., Kikuchi A., Kubo H., Sasaki H. Randomized phase II trial comparing nitroglycerin plus vinorelbine and cisplatin with vinorelbine and cisplatin alone in previously untreated stage IIIB/IV non-small cell lung cancer. J. Clin. Oncol. 2006, 24:688-694.
75. Yasuda H., Nakayama K., Watanabe M., Suzuki S., Fuji H., Okinaga S., Kanda A., Zayazu K., Sasaki T., Asada M., Suzuki T., Yoshida M., Yamanda S., Inoue D., Kaneta T., Kondo T., Takai Y., Sasaki H., Yanagihara K., Yamaya M. Nitroglycerin treatment may increase response to docetaxel and carboplatin regimen via inhibitions of hypoxia-inducible factor-1 pathway and P-glycoprotein in patients with lung adenocarcinoma. Clin. Cancer Res. 2006, 12:6748-6757.
76. Yasuda H., Yanagihara K., Nakayama K., Mio T., Sasaki T., Asada M., Yamaya M., Fukushima M. Therapeutic applications of nitric oxide for malignant tumor in animal models and human studies. Nitric Oxide and Cancer 2010, 419-441. Springer Science, New York. B. Bonavida (Ed.).
77. Siemens D.R., Heaton J.P.W., Adams M.A., Kawakami J., Graham C.H. Phase II study of nitric oxide donor for men with increasing prostate-specific antigen level after surgery or radiotherapy for prostate cancer. Urology 2009, 74:878-883.
78. Noguchi A., Takahashi T., Yamaguchi T., Kitamura K., Noguchi A., Tsurumi H., Takashina K., Maeda H. Enhanced tumor localization of monoclonal antibody by treatment with kininase II inhibitor and angiotensin II. Jpn. J. Cancer Res. 1992, 83:240-243.
79. Li C.J., Miyamoto Y., Kojima Y., Maeda H. Augmentation of tumour delivery of macromolecular drugs with reduced bone marrow delivery by elevating blood pressure. Br. J. Cancer 1993, 67:975-980. M.R.
80. Fang J., Qin H., Nakamura H., Tsukigawa K., Maeda H. Carbon monoxide, generated by heme oxygenase-1, mediates the enhanced permeability and retention (EPR) effect of solid tumor. Cancer Sci. 2012, 102:535-541.
81. Kano, Bae Y., Iwata C., Morishita Y., Yashiro M., Oka M., Fujii T., Komuro A., Kiyono K., Kaminishi M., Hirakawa K., Ouchi Y., Nishiyama N., Kataoka K., Miyazono K. Improvement of cancer-targeting therapy, using nanocarriers for intractable solid tumors by inhibition of TGF-β signaling. Proc. Natl. Acad. Sci. U. S. A. 2007, 104:3460-3465.
82. Seki T., Carroll F., Illingworth S., Green N., Cawood R., Bachtarzi H., Subr V., Fisher K.D., Seymour L.W. Tumour necrosis factor-alpha increases extravasation of virus particles into tumour tissue by activating the Rho A/Rho kinase pathway. J. Control. Release 2011, 156:381-389.